By a News Reporter-Staff News Editor at Biotech Week -- Research findings on Drugs and Therapies are discussed in a new report. According to news reporting from Durham, North Carolina, by NewsRx journalists, research stated, "BackgroundAdvances in implantable cardioverter defibrillator (ICD) technology have resulted in more effective defibrillation, and the need for defibrillation threshold (DFT) testing has been questioned. MethodsA total of 64,227 initial ICD implant procedures performed at 1,261 facilities (April to December 2010) in the NCDR Registry were selected to identify patterns of practice related to DFT testing."
The news correspondents obtained a quote from the research from Duke University, "physician, and procedural characteristics were compared. Independent association of DFT testing with in-hospital adverse events or mortality was also examined. ResultsDFT testing was performed in 71% of patients. Patients who did not undergo testing were older; more often had heart failure, lower left ventricular ejection fraction, atrial arrhythmias, and a primary prevention indication; and were more likely to receive a cardiac resynchronization therapy device. In addition, patients who did not undergo testing were less likely to be implanted in a metropolitan area and more often implanted at a teaching hospital, in New England, in the Mid-Atlantic, or in the Pacific U.S. In-hospital adverse events occurred in 2.56% of patients who underwent DFT testing compared to 3.58% who did not (P < 0.001). Death or any complication remained more likely to occur in patients who did not undergo testing (odds ratio and 95% confidence interval: 1.46 [1.33, 1.61], P< 0.001), after adjusting for baseline and procedural differences. ConclusionsDFT testing is not performed in many (29%) patients in clinical practice. Patients who did not undergo testing were more likely to have adverse events and to be older with more comorbidities, which could explain why DFT testing was avoided."
According to the news reporters, the research concluded: "Prospective randomized data are needed to determine the impact of DFT testing on outcome."
For more information on this research see: Patient, Physician, and Procedural Factors Influencing the Use of Defibrillation Testing during Initial Implantable Cardioverter Defibrillator Insertion: Findings from the NCDR ®. PACE-Pacing and Clinical Electrophysiology, 2013;36(12):1522-1531. PACE-Pacing and Clinical Electrophysiology can be contacted at: Wiley-Blackwell, 111 River St, Hoboken 07030-5774, NJ, USA (see also Drugs and Therapies).
Our news journalists report that additional information may be obtained by contacting A.M. Russo, Duke University, Sch Med, Durham, NC, United States. Additional authors for this research include Y.F. Wang, S.M. Al-Khatib, J.P. Curtis and R. Lampert.
Keywords for this news article include: Durham, Hospital, United States, North Carolina, Defibrillators, Medical Devices, Drugs and Therapies, Adverse Drug Reaction, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC